Henry Koon
About Henry Koon
Henry Koon is a Clinical Trial Lead at Bristol-Myers Squibb with over 25 years of experience in oncology and clinical trials.
Company
Henry Koon is currently working at Bristol-myers Squibb in New Jersey, United States. In his role as Clinical Trial Lead, he is responsible for overseeing clinical trials and ensuring their compliance with regulatory standards. Bristol-myers Squibb is known for its work in biopharmaceuticals, focusing on the discovery, development, and delivery of innovative medicines.
Title
Henry Koon holds the position of Clinical Trial Lead at Bristol-myers Squibb. This role demands rigorous oversight of clinical trials, including planning, execution, and management of resources. His focus is on ensuring that clinical trials are conducted according to regulatory standards and contribute to the development of new therapies.
Background
Henry Koon has a robust background in both clinical and academic settings. He served at Seidman Cancer Center Case Western Reserve Medical School as Associate Professor, Hematology and Oncology, and Director of the Medical Oncology Program in Cutaneous Malignancy from 2015 to 2017. Prior to that, he was an Assistant Professor, Hematology and Oncology, and Director of the same program from 2007 to 2015. He also worked at Beth Israel Deaconess Medical Center as an Attending Physician in the Cutaneous Oncology Program from 1997 to 2007.
Education and Expertise
Henry Koon has an extensive educational background in medicine and pharmacy, having studied at the University of Mississippi School of Medicine from 1990 to 1994. He also studied at the University of Mississippi, where he earned a Bachelor of Science in Pharmacy, spending nine years from 1981 to 1990. His focused education laid the groundwork for a distinguished career in oncology and clinical trials, with over 25 years of experience in the field.
Achievements
Throughout his career, Henry Koon has led multiple clinical trials with a particular focus on cutaneous malignancies. During his tenure at Seidman Cancer Center, he contributed to the development of new treatment protocols for skin cancer. His work in hematology and oncology, particularly at Case Western Reserve Medical School, involved pioneering research projects. He has managed and directed medical oncology programs, significantly impacting the treatment landscape for skin cancer patients.